{"id":18221,"date":"2014-07-11T02:30:00","date_gmt":"2014-07-11T00:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/avastin-lucentis-il-caso-diventa-europeo-risparmi-per-milioni-di-euro-con-loff-label-2\/"},"modified":"2014-07-11T02:30:00","modified_gmt":"2014-07-11T00:30:00","slug":"avastin-lucentis-il-caso-diventa-europeo-risparmi-per-milioni-di-euro-con-loff-label-2","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/avastin-lucentis-il-caso-diventa-europeo-risparmi-per-milioni-di-euro-con-loff-label-2\/","title":{"rendered":"Avastin-Lucentis, the case becomes European: savings of millions of euros with the &quot;off-label&quot;"},"content":{"rendered":"<p><span style=\"font-size: large;\">&nbsp;<span style=\"color: rgb(0, 56, 107); font-family: Arial, sans-serif; line-height: 15pt;\">Gross price differences between the two ophthalmic drugs. France wants to imitate Italy and the Pharmaceutical Industries Association calls the EU into question. The issue of healthcare costs and that of patient safety. New therapeutic indications<\/span><\/span><\/p>\n<p class=\"MsoNormal\" style=\"margin-bottom:6.0pt\"><i><span style=\"font-size:9.0pt; line-height:107%;font-family:&quot;inherit&quot;,&quot;serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;; mso-bidi-font-family:Arial;color:#555555;border:none windowtext 1.0pt; mso-border-alt:none windowtext 0cm;padding:0cm;mso-fareast-language:IT\">by MAURIZIO PAGANELLI 10 July 2014 \u2013 &nbsp;<\/span><\/i><span style=\"font-size:9.0pt; line-height:107%;font-family:&quot;Arial&quot;,&quot;sans-serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;; color:#555555;border:none windowtext 1.0pt;mso-border-alt:none windowtext 0cm; padding:0cm;mso-fareast-language:IT;mso-bidi-font-style:italic\"><a href=\"http:\/\/www.repubblica.it\/salute\/2014\/07\/10\/news\/avastin-lucentis_il_caso_diventa_europeo-91232981\/\" target=\"_blank\" rel=\"noopener\">La Repubblica.it Health<\/a><\/span><i><span style=\"font-size:9.0pt;line-height: 107%;font-family:&quot;inherit&quot;,&quot;serif&quot;;mso-fareast-font-family:&quot;Times New Roman&quot;; mso-bidi-font-family:Arial;color:#555555;border:none windowtext 1.0pt; mso-border-alt:none windowtext 0cm;padding:0cm;mso-fareast-language:IT\"><\/p>\n<p><\/span><\/i><\/p>\n<p class=\"MsoNormal\" style=\"margin-bottom:6.0pt\"><span style=\"font-size: large;\"><span style=\"font-family: Arial, sans-serif; color: rgb(34, 34, 34); background-image: initial; background-attachment: initial; background-size: initial; background-origin: initial; background-clip: initial; background-position: initial; background-repeat: initial;\">THE story of the drug Lucentis for senile macular degeneration BECOMES a European case (cost 902 euros, but effective with discounts of around 600 euros per vial) and&nbsp;<\/span><\/span><a href=\"http:\/\/www.repubblica.it\/salute\/medicina\/2014\/05\/15\/news\/css_i_farmaci_avastin_e_lucentis_sono_del_tutto_equivalenti-86207263\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-size: large;\"><span style=\"font-family: Arial, sans-serif; color: rgb(0, 56, 107); border: 1pt none windowtext; padding: 0cm; text-decoration: none; background-image: initial; background-attachment: initial; background-size: initial; background-origin: initial; background-clip: initial; background-position: initial; background-repeat: initial;\">of his &quot;alternative&quot;<\/span><\/span><\/a><span style=\"font-size: large;\"><span style=\"font-family: Arial, sans-serif; color: rgb(34, 34, 34); background-image: initial; background-attachment: initial; background-size: initial; background-origin: initial; background-clip: initial; background-position: initial; background-repeat: initial;\">&nbsp;10 or 30 times cheaper,<\/span><\/span><a href=\"http:\/\/www.repubblica.it\/salute\/medicina\/2014\/06\/10\/news\/farmaci_aifa_via_libera_a_avastin_per_degenerazione_maculare-88591351\/\" target=\"_blank\" rel=\"noopener\"><span style=\"font-size: large;\"><span style=\"font-family: Arial, sans-serif; color: rgb(0, 56, 107); border: 1pt none windowtext; padding: 0cm; text-decoration: none; background-image: initial; background-attachment: initial; background-size: initial; background-origin: initial; background-clip: initial; background-position: initial; background-repeat: initial;\">Avastin<\/span><\/span><\/a><span style=\"font-size: large;\"><span style=\"font-family: Arial, sans-serif; color: rgb(34, 34, 34); background-image: initial; background-attachment: initial; background-size: initial; background-origin: initial; background-clip: initial; background-position: initial; background-repeat: initial;\">, an anti-cancer used off-label, i.e. outside its specific therapeutic indications and not authorized for ofta use<\/p>","protected":false},"excerpt":{"rendered":"<p>&nbsp;Differenze macroscopiche di prezzo tra i due farmaci oftalmici. La Francia vuole imitare l&rsquo;Italia e l&rsquo;Associazione industrie farmaceutiche chiama in causa la Ue. La questione dei costi sanitari e quella della sicurezza dei pazienti. Nuove indicazioni terapeutiche di MAURIZIO PAGANELLI 10 luglio 2014&nbsp; &#8211; &nbsp;La Repubblica.it Salute DIVENTA un caso europeo la vicenda del farmaco &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-18221","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/18221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=18221"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/18221\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=18221"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=18221"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=18221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}